You just read:

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age

News provided by

Astellas Pharma US, Inc.

Jan 08, 2020, 15:30 ET